Effect of Buparlisib, a Pan-Class I PI3K Inhibitor, in Refractory Follicular and Poorly Differentiated Thyroid Cancer
Thyroid2018Vol. 28(9), pp. 1174–1179
Citations Over TimeTop 12% of 2018 papers
Françoise Borson‐Chazot, Emmanuelle Dantony, F. Illouz, Jonathan Lopez, Patricia Niccoli, Johanna Wassermann, Christine Do Cao, Sophie Leboulleux, Marc Klein, Antoine Tabarin, Eberle Mc, Danielle Benisvy, Christelle de la Fouchardière, Claire Bournaud, Hélène Lasolle, Armelle Delahaye, Muriel Rabilloud, Lapras, Myriam Decaussin‐Petrucci, Martin Schlumberger, the TUTHYREF Network
Abstract
Buparlisib did not result in significant efficacy in advanced FTC and PDTC. However, the decrease in tumor growth rate may suggest incomplete inhibition of oncogenic pathways and/or escape mechanisms. This should lead to evaluate combined therapy associating inhibitors of both the PI3K and mitogen-activated protein kinase pathways.
Related Papers
- → Epigenetic Modifications: Novel Therapeutic Approach for Thyroid Cancer(2017)20 cited
- → ANALYSIS OF RELAPSE RATE AND METASTASES OF HIGH DIFFERENTIATED THYROID CANCER(2015)1 cited
- → Follow-up Strategy in Follicular Thyroid Cancer(2006)
- → Follicular Thyroid Cancer(2000)
- Morphometry Study on the Structure of Thyroid Gland at Different Growth Stages in Pigs(2012)